Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Lymphoma 2 Lung Neoplasms 2 Hematologic Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Meningioma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Glioma 1 Exanthema 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Diarrhea 1

Interventions

Octreotide 2 telotristat ethyl 1 isatuximab 1 ceterizine hydrochloride 1 capivasertib 1 cabazitaxel 1 XRP6258 1 Prednisone 1 Loperamide 1 Leucovorin 1 Lapatinib 1 Irinotecan 1 Injections 1 Granulocyte Colony-Stimulating Factor 1 Fulvestrant 1 Fluorouracil 1 Filgrastim 1 Drugs, Investigational 1 Cyclophosphamide 1 Colesevelam Hydrochloride 1 Cell- and Tissue-Based Therapy 1 Capecitabine 1 Calcium Aluminosilicate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Diarrhea × capivasertib × Clear all

NCT07426822 2026-02-24

SAFE-CAP

Yale University

Phase 2 Not yet recruiting

Diarrhea, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡